Champions Oncology, Inc.
CSBR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000771856
No open-market purchases or sales by Champions Oncology, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $36.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 28
- 13F valueReported value at the end of Q2 2026
- $36.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CSBR, Q2 2026
No superinvestor reported holding CSBR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Champions Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 (view filing) | Jan 12 | 4 days | Mendelson Daniel NewmanDirector | PPurchase | +1.00K | $6.50 | +$6.50K | +0.5%198.6K after | |
| Jan 12, 2024 (view filing) | Jan 11 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +2.00K | $6.27 | +$12.5K | +1.0%197.6K after | |
| Jan 11, 2024 (view filing) | Jan 10 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +2.94K | $6.31 | +$18.6K | +1.5%195.6K after | |
| Jan 10, 2024 (view filing) | Jan 9 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +3.00K | $6.25 | +$18.8K | +1.6%192.7K after | |
| Jan 9, 2024 (view filing) | Jan 8 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +1.00K | $6.15 | +$6.15K | +0.5%189.7K after | |
| Jan 8, 2024 (view filing) | Jan 5 | 3 days | Mendelson Daniel NewmanDirector | PPurchase | +2.00K | $6.09 | +$12.2K | +1.1%188.7K after | |
| Jan 8, 2024 (view filing) | Jan 4 | 4 days | Mendelson Daniel NewmanDirector | PPurchase | +3.00K | $6.12 | +$18.4K | +1.6%186.7K after | |
| Jan 4, 2024 (view filing) | Jan 3 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +500 | $5.83 | +$2.92K | +0.3%183.7K after | |
| Dec 26, 2023 (view filing) | Dec 21 | 5 days | Mendelson Daniel NewmanDirector | PPurchase | +2.50K | $4.92 | +$12.3K | +1.4%183.2K after | |
| Dec 21, 2023 (view filing) | Dec 20 | 1 day | Mendelson Daniel NewmanDirector | PPurchase | +2.10K | $4.82 | +$10.1K | +1.2%180.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Champions Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Battery Management Corp. | 2,421,673 | $14.9M | 4.05% | 00.0% | Unchanged |
| NEA Management Company, LLC | 1,713,720 | $10.6M | 0.66% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 301,353 | $1.86M | 0.00% | +1,833+0.6% | Added |
| Tocqueville Asset Management L.P. | 295,658 | $1.82M | 0.02% | −24,016−7.5% | Reduced |
| Morgan Stanley | 235,400 | $1.45M | 0.00% | −6,900−2.8% | Reduced |
| Bank of America Corp | 214,058 | $1.32M | 0.00% | +192,225+880.4% | Added |
| Renaissance Technologies LLC | 139,039 | $856.5K | 0.00% | −6,500−4.5% | Reduced |
| BlackRock, Inc. | 129,848 | $799.9K | 0.00% | +5,948+4.8% | Added |
| Mink Brook Asset Management LLC | 111,338 | $685.8K | 0.30% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 76,300 | $470.1K | 0.00% | −877−1.1% | Reduced |